Clinical Trial Update: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) [Phase 2]

View source ↗

Summary

The Phase 2 study CLIN-012 evaluating CST-103 co-administered with CST-107 in Parkinson's disease patients with freezing of gait has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• CST-103
• CST-107

Snippet

Sponsor: CuraSen Therapeutics, Inc. | Conditions: Freezing of Gait Symptoms in Parkinson's Disease | Phase 2 | Status: WITHDRAWN